### Astec LifeSciences Reports No Deviations in Right Issue Proceeds

Date: October 29, 2025

In a recent filing to the National Stock Exchange of India, Astec LifeSciences Limited announced that there were no deviations or variations in the utilization of proceeds from its Right Issue of equity shares for the quarter ending September 30, 2025. This disclosure was made in accordance with Regulation 32 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements.

Astec LifeSciences confirmed that the funds raised through the Right Issue are being utilized as intended, reflecting the company's commitment to transparency and regulatory compliance. The company’s proactive communication reinforces investor confidence, assuring stakeholders that the capital is being allocated effectively.

The announcement, submitted by Tejashree Pradhan, the Company Secretary and Compliance Officer, emphasizes Astec's adherence to financial regulations while maintaining operational integrity. By consistently updating the market, Astec LifeSciences aims to uphold its reputation as a responsible corporate entity.

For investors and stakeholders in the pharmaceutical and life sciences sector, this news underscores Astec LifeSciences' prudent financial management practices and dedication to shareholder value.

Stay tuned for more updates from Astec LifeSciences and other corporate announcements that could impact the market.

Keywords: Astec LifeSciences, Right Issue, SEBI Regulations, Corporate Governance, Financial Transparency, Investor Confidence

---

This SEO-friendly summary is designed to engage readers while adhering to best practices for optimized content on WordPress.